Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Kidney Cancer Drugs Market
Kidney Cancer Drugs Market Size
- Report ID: GMI10004
- Published Date: Jun 2024
- Report Format: PDF
Kidney Cancer Drugs Market Size
Kidney Cancer Drugs Market size was valued at USD 6.2 billion in 2023 and is expected to exhibit growth at a CAGR of 5.6% from 2024 – 2032. High market growth can be attributed to the ongoing advancements in treatment modalities, increasing incidence of kidney cancer, rising healthcare expenditure, and expanding pipeline of novel therapeutics, among other contributing factors.
Moreover, kidney cancer incidence has been steadily increasing globally due to factors such as aging populations, lifestyle changes (e.g., smoking, obesity), and environmental exposures. For instance, according to the American Society of Clinical Oncology (ASCO), in 2023, approximately 81,800 individuals in the U.S. (52,360 men and 29,440 women) were diagnosed with kidney cancer. As the prevalence of kidney cancer rises, there is a growing demand for effective treatment options, driving the growth of the kidney cancer drugs market.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Kidney Cancer Drugs Market Size in 2023: | USD 6.2 Billion |
| Forecast Period: | 2024 - 2032 |
| Forecast Period 2024 - 2032 CAGR: | 5.6% |
| 2032 Value Projection: | USD 10 Billion |
| Historical Data for: | 2021 – 2023 |
| No. of Pages: | 110 |
| Tables, Charts & Figures: | 181 |
| Segments covered: | Cancer Type, Therapy, Drug Class, Route of Administration, Distribution Channel, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Furthermore, increasing healthcare expenditure, particularly in developed countries, supports greater access to advanced or rapid diagnostics tools, treatment options, and supportive care services for kidney cancer patients. Higher healthcare spending translates into increased demand for kidney cancer drugs, driving market growth. Additionally, expanding access to healthcare in emerging economies contributes to market expansion in those regions.
Kidney cancer drugs refer to medications and therapies used in the treatment of kidney cancer, also known as renal cell carcinoma (RCC) or renal cell adenocarcinoma. These drugs are designed to target cancer cells, inhibit their growth, and/or enhance the body's immune response against the cancer.
Frequently Asked Questions (FAQ) :
Kidney Cancer Drugs Market Scope
